Dexcom (DXCM) Cash from Investing Activities (2010 - 2026)

Dexcom (DXCM) has 17 years of Cash from Investing Activities data on file, last reported at -$298.5 million in Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$298.5 million, down 397.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $137.3 million (up 175.4% YoY), and the FY2025 annual result was $536.0 million, up 358.31% from the prior year.
• Cash from Investing Activities eased to -$298.5 million in Q1 2026 per DXCM's latest filing, from $306.6 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $414.9 million in Q4 2023 and troughed at -$555.9 million in Q2 2023.
• A 5-year average of -$58.7 million and a median of -$144.9 million in 2022 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2026: Cash from Investing Activities surged 690.69% in 2022, then sank 397.9% in 2026.
• A 5-year view of Cash from Investing Activities shows it stood at -$194.1 million in 2022, then surged by 313.76% to $414.9 million in 2023, then tumbled by 173.2% to -$303.7 million in 2024, then jumped by 200.95% to $306.6 million in 2025, then plunged by 197.36% to -$298.5 million in 2026.
• Business Quant data shows DXCM's Cash from Investing Activities at -$298.5 million in Q1 2026, $306.6 million in Q4 2025, and $192.8 million in Q3 2025.